Provided by Tiger Trade Technology Pte. Ltd.

ARS PHARMACEUTICALS INC

5.35
-0.1550-2.82%
Post-market: 5.350.00000.00%19:55 EDT
Volume:1.94M
Turnover:10.30M
Market Cap:532.04M
PE:-2.46
High:5.46
Open:5.40
Low:5.20
Close:5.51
52wk High:14.00
52wk Low:4.91
Shares:99.45M
Float Shares:48.03M
Volume Ratio:1.07
T/O Rate:4.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1757
EPS(LYR):-1.7400
ROE:-210.35%
ROA:-48.02%
PB:42.52
PE(LYR):-3.07

Loading ...

Top Premarket Decliners

MT Newswires Live
·
Jun 25

Stocks to Watch: Micron, ARS Pharmaceuticals, Millerknoll, Passage Bio

Dow Jones
·
Jun 25

Shares of ARS Pharmaceuticals Fall After no New Commercial Insurers Add Neffy

Dow Jones
·
Jun 25

ARS reports no new commercial formulary additions, coverage decisions for neffy

TIPRANKS
·
Jun 25

ARS Pharma Cuts 2026 Cash Operating Expense Outlook to $248 Million Excluding COGS

Reuters
·
Jun 25

ARS Pharmaceuticals Inc: Total 2026 Cash-based Operating Expenses, Excluding Cogs, Lowered to $248 Mln

THOMSON REUTERS
·
Jun 25

ARS Pharmaceuticals Inc: Reaffirms Neffy Base Business Supports a Path to Cash-flow Breakeven in 2027

THOMSON REUTERS
·
Jun 25

ARS Pharmaceuticals - no New Commercial Formulary Additions for Neffy in July 1, 2026 Cycle

THOMSON REUTERS
·
Jun 25

ARS Pharmaceuticals Provides Commercial and Financial Updates

THOMSON REUTERS
·
Jun 25

ARS Pharma Chief Commercial Officer Eric Karas sells 25,000 shares for $250,000

Reuters
·
Jun 13

ARS Pharma Chief Legal Officer Alexander Fitzpatrick sells 3,355 shares for $33,550

Reuters
·
Jun 13

Drew Brees Collaborates With ARS Pharmaceuticals to Raise Awareness About Living Life With Severe Allergies

THOMSON REUTERS
·
Jun 04

ARS Pharmaceuticals files Form 3 for President Donn Casale, reporting no beneficial ownership

Reuters
·
Jun 02

ARS Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
May 28

ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

BUZZ-U.S. STOCKS ON THE MOVE-Cerebras, Papa John's, airline stocks

Reuters
·
May 15

ARS Pharma Q1 FY26 net loss widens to $60.62 million; revenue more than doubled to $22.68 million

Reuters
·
May 15

ARS Pharmaceuticals Q1 Loss Widens, Revenue Rises; Shares Up Pre-Bell

MT Newswires Live
·
May 15

ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth

Reuters
·
May 15

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Loss $0.61 a Share, vs. FactSet Est of $0.49 Loss

MT Newswires Live
·
May 15